History

Achieving the best results in diagnostic research requires a strong knowledge base, expertise, commitment and constant attention to technological innovation.

With this spirit, for over thirty years, Technogenetics has offered its consolidated experience gained by operating in international environments and establishing strong local ties. This synergistic process and opening to the markets has made Technogenetics one of the best-known and best-thought-of industry players.

2015 - KHB acquires Technogenetics

Listed on the Shenzhen Stock Exchange, KHB is a leading manufacturer of in vitro diagnostic kits in China. Its business activities are centered around Research & Development and on the production and marketing of reagents and laboratory instruments, with special focus on hepatitis, HIV, tumor markers, infectious diseases, autoimmunity and endocrinology.

2014 - Introduction of the new TGS TA Toxo, Rubella and CMV kits and implementation of the infectious disease ToRCH panel using chemiluminescence.

2014 - Thanks to its partnership with Altergon Italia, the company starts expanding its R&D activities on immunodiagnostic products at the Irpinia site, as well as an in vitro diagnostics internationalization program in China.

2013 - Manufacturing, sales and logistics are transferred to the company's modern dedicated site in Lodi, which ensures high quality standards and greater manufacturing capacity.

2013 – Development for the Italian market of GOLDchip® constitutional, the first CGH array platform for prenatal genetic screening, entirely designed by Technogenetics.

2012 - Presentation of the infectious disease line on Technogenetics Total Automation, the new chemiluminescence TGS TA random access platform, and launch on the market of the first TGS TA HSV and EBV analytes.

2010 - Agreement with MENARINI Diagnostics for the marketing of chemiluminescence autoimmune assay kits.

2009 - Acquisition of Bouty and Technogenetics by IBSA Farmaceutici.

2007 - Technogenetics develops a new chemiluminescence platform for autoimmune and infectious diseases.

2005 - As a result of the Bouty Group's internal business reorganization, the manufacture, distribution and marketing of all Diagnostics Division products are transferred to Technogenetics.

In an increasingly dynamic market, Technogenetics decides to invest in a strategic and innovative segment, and starts the Group's activities in the area of molecular genetics.

2001 - Technogenetics introduces on the Italian market its line of automated ELISA kits for DSX instrument, an innovative next-generation ELISA processor.

1998 - As distributor of the BEIA line for infectious diseases and the MyRIA & Lisophase product lines, Technogenetics is a market leader in the fields of infectious diseases and endocrinology.

1994 – Technogenetics becomes part of the Bouty Group. Since the late 1970s, Bouty has operated in the infectious diseases segment as distributor of third-party products and manufacturer of its own line of kits. The acquisition increases the Group's expertise base and gives a new boost to the Diagnostics division.

1986 - Technogenetics is part of RECORDATI Group.

1982 - Foundation of Technogenetics.